BioSpace News Archive

On March 31, Cambridge, Massachusetts-based Nuvalent announced that Anna Protopapas has been appointed as Chair of its Board of Directors.

Bristol Myers Squibb announced results from the Phase 3 VALOR-HCM study, which showed the addition of mavacamten, an investigational, first-in-class cardiac myosin inhibitor, significantly reduced the need for septal reduction therapy in patients with severely symptomatic obstructive hypertrophic cardiomyopathy who had been appropriate for SRT per the 2011 American College of Cardiology/American Heart Association Guidelines at baseline.

Lundbeck announced new data from an oral abstract for VYEPTI®, along with three poster presentations, are being presented at the 2022 Annual Scientific Meeting of the American Academy of Neurology, which is being held in person from April 2-7 and virtually from April 24-26.

Lexicon Pharmaceuticals, Inc. announced results of a new analysis of data from the SCORED Phase 3 clinical trial of sotagliflozin that was presented at the American College of Cardiology’s 71st Annual Scientific Session.

Cytokinetics, Incorporated announced that the full results from Cohort 3 of REDWOOD-HCM, the Phase 2 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy, were presented in a Moderated Poster Session by Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Assistant Professor of Medicine, University of Pennsylvania, at the American College of Cardiology 71st Annual Scientific Session.

Amylyx Pharmaceuticals, Inc. announced the presentation of safety and tolerability data on AMX0035 as assessed in the CENTAUR and PEGASUS clinical trials in participants with amyotrophic lateral sclerosis and Alzheimer’s disease, respectively.